180 related articles for article (PubMed ID: 7041358)
1. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
Cosimi AB; Burton RC; Colvin RB; Goldstein G; Delmonico FL; LaQuaglia MP; Tolkoff-Rubin N; Rubin RH; Herrin JT; Russell PS
Transplantation; 1981 Dec; 32(6):535-9. PubMed ID: 7041358
[TBL] [Abstract][Full Text] [Related]
2. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection.
Thistlethwaite JR; Cosimi AB; Delmonico FL; Rubin RH; Talkoff-Rubin N; Nelson PW; Fang L; Russell PS
Transplantation; 1984 Dec; 38(6):695-701. PubMed ID: 6390834
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.
Leone MR; Barry JM; Alexander SR; Melvin T; Striegel J; Reller K; Henell KR; Kimball J; Funnell MB; Goldstein G
J Pediatr; 1990 May; 116(5):S86-91. PubMed ID: 2139465
[TBL] [Abstract][Full Text] [Related]
4. OKT3 treatment of steroid-resistant renal allograft rejection.
Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
[TBL] [Abstract][Full Text] [Related]
5. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.
Ortho Multicenter Transplant Study Group
N Engl J Med; 1985 Aug; 313(6):337-42. PubMed ID: 2861567
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection.
Norman DJ; Shield CF; Barry JM; Henell K; Funnell MB; Lemon J
Nephron; 1987; 46 Suppl 1():41-7. PubMed ID: 3306424
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte function in patients treated with monoclonal anti-T3 antibody for acute cadaveric renal allograft rejection.
Bowen A; Edwards LC; Gailiunas P; Helderman JH
Transplantation; 1984 Nov; 38(5):489-93. PubMed ID: 6388070
[TBL] [Abstract][Full Text] [Related]
9. Monitoring immunosuppression following renal transplantation.
Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
[TBL] [Abstract][Full Text] [Related]
10. Experience with OKT3 in vascularized pancreas transplantation.
Sollinger HW; Stratta RJ
Am J Kidney Dis; 1988 Feb; 11(2):145-8. PubMed ID: 3277405
[TBL] [Abstract][Full Text] [Related]
11. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.
Cosimi AB; Colvin RB; Burton RC; Rubin RH; Goldstein G; Kung PC; Hansen WP; Delmonico FL; Russell PS
N Engl J Med; 1981 Aug; 305(6):308-14. PubMed ID: 6454075
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.
Vigeral P; Chkoff N; Chatenoud L; Campos H; Lacombe M; Droz D; Goldstein G; Bach JF; Kreis H
Transplantation; 1986 Jun; 41(6):730-3. PubMed ID: 3520988
[TBL] [Abstract][Full Text] [Related]
13. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
Chatenoud L; Bach JF
Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
[TBL] [Abstract][Full Text] [Related]
15. OKT3: First-dose safety and success.
Cosimi AB
Nephron; 1987; 46 Suppl 1():12-8. PubMed ID: 3306421
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
17. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.
Norman DJ; Shield CF; Barry J; Bennett WM; Henell K; Kimball J; Funnell B; Hubert B
Am J Kidney Dis; 1988 Feb; 11(2):107-10. PubMed ID: 3277400
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.
Norman DJ; Shield CF; Henell KR; Kimball J; Barry JM; Bennett WM; Leone M
Transplantation; 1988 Oct; 46(4):523-9. PubMed ID: 3140448
[TBL] [Abstract][Full Text] [Related]
19. Delayed response to orthoclone OKT3 treatment for renal allograft rejection resistant to steroid and antilymphocyte globulin.
Oh CS; Sollinger HW; Stratta RJ; Kalayoglu M; Belzer FO
Transplantation; 1988 Jan; 45(1):65-7. PubMed ID: 3276065
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
